ARTICLE | Company News
Isis, OncoGenex Technologies deal
September 15, 2003 7:00 AM UTC
The companies expanded their 2001 deal to co-develop and market OGX-011 to treat prostate cancer. The antisense compound inhibits clusterin. As expanded, the partnership will include second-generati...